I thank the Member for that question, Llywydd. The news that the regulator has approved a new antiviral oral medicine is good news. We have been in discussions with the UK department of health. What is planned is a large-scale study, using those 480,000 doses. And that study will be used to identify, in the way that the Member suggested, the clinical circumstances in which that treatment can most effectively be delivered. Wales will be part of that pilot. There will be patients in Wales who will be part of the work that will be carried out to make sure that we are learning everything we need to about this new possibility and then put it to best use. And we continue to work closely with the UK department on this matter to make sure that Welsh patients have access to the treatment and that we all benefit from the work that will be carried out.